MedTrace Logo

Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab

NCT01250678 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2010-12-01

No results posted yet for this study

Summary

Cognitive impairment is seen in about half of patients with relapsing remitting MS. Our knowledge about long term development of cognitive performance under natalizumab therapy is limited. We want to demonstrate with this study that patients treated with ntz improve in neurocognitive tests over the long term.

Conditions

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • Cantonal Hospital of St. Gallen

    lead OTHER

Principal Investigators

  • Murat Yildiz, MD · Cantonal Hospital Saint Gallen

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2014-01-31
Completion
2014-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01250678 on ClinicalTrials.gov